BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AVZO-1418 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AVZO-1418\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07038343-2369@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:AVZO-1418: Phase 1/2 readout est. (NCT07038343)
DESCRIPTION:AVZO-1418\, phase 1/2.\nStudy: AVENTINE-1: Study of AVZO-1418 a
 s a Single Agent and in Combination Therapy in Patients With Locally Advan
 ced or Metastatic Solid Tumors (AVZO-1418-1001)\nEstimated primary complet
 ion: June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/avzo-
 1418#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07038343
URL:https://assetmemo.bio/drug/avzo-1418#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
